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Abstract. According to the literature, the APP Ala713Thr mutation is associated with Alzheimer’s disease and cerebral
amyloid angiopathy. We describe a case of dementia clinically compatible with frontotemporal dementia in an APP Ala713Thr
mutation carrier in which both [18F]Florbetapir PET uptake and A1-42 cerebrospinal fluid levels were normal. Further
evidences are required to establish if this association is only incidental.
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INTRODUCTION
The revised National Institute on Aging-
Alzheimer’s Association (NIA-AA) diagnostic
criteria for dementia due to Alzheimer’s disease
(AD) encourage the use of biomarkers in order to
improve AD cases identification [1], and according
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University of Florence, Viale Pieraccini 6, 50139 Florence,
Italy. Tel.: +39 055 7948910; Fax: +39 0552758265; E-mail:
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to International Working Group-2 (IWG-2) research
diagnostic criteria, the diagnosis of AD relies on the
presence of a pathophysiological marker [2]. The
accuracy of amyloid positron emission tomography
(PET) imaging in detecting amyloid- (A) plaques
has been demonstrated [3], and some authors have
found a correlation between low cerebrospinal
fluid (CSF) A1-42 levels and a high number of
plaques in the brain [4] as well as a high in vivo
amyloid PET uptake [5]. In the occurrence of an
AD causative mutation, the certainty that dementia
is caused by AD pathology is increased according
ISSN 1387-2877/17/$35.00 © 2017 – IOS Press and the authors. All rights reserved
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to NIA-AA criteria, whereas applying the IWG
research criteria, the genetic evidence is compatible
to definite AD [6].
Among APP mutations, the APP Ala713Thr was
considered by some authors as a possible non-
pathogenic polymorphism [7]; more recently, the
variant has been associated with autosomal domi-
nant familial AD (FAD) with cerebrovascular lesions
in Calabrian families [8, 9], and no relevant dif-
ferences in clinical phenotype were found between
heterozygous and homozygous patients, according to
the definition of dominance [9].
MATERIAL AND METHODS
A 51-year-old Italian man was admitted to our
clinic because of gradual change in behavior and
personality, cognitive decline, and urinary inconti-
nence; symptoms started one year before the first
visit. Family history included a maternal aunt affected
by unspecified early onset dementia (55 years) who
died at the age of 75. No other cases of neurodegen-
erative/vascular dementia were known in the family.
The mother died at 76 years because of renal failure
in diabetes mellitus, while the father was affected by
syphilis and died at the age of 78 years.
Information about health status of his cousins
were not available. The patient underwent clinical-
neuropsychological assessment and conventional
brain magnetic resonance imaging (MRI); sub-
sequently, since the diagnosis was uncertain,
supplemental investigations on biomarkers were per-
formed: brain [18F]fluorodeoxyglucose ([18F]FDG)
PET, CSF analysis, genetic analysis for frontotem-
poral dementia (FTD), genetic analysis for FAD and
lastly amyloid PET. All exams, except the amyloid
PET, were carried out one year after the symp-
toms onset (baseline); neuropsychological evaluation
was performed at baseline and at 6-month follow-up
(Table 1), while amyloid PET was made 3 years after
the symptoms onset.
The extensive neuropsychological evaluation was
conducted with the Mini-Mental State Examination
(MMSE) [10] and by tests assessing memory (Rey
Auditory Verbal Learning Test [11], Babcock Story
Recall Test [12], Digit Span Forward and Backward
[13]), attention (Trail Making Test A and B [12]), lan-
guage (Verbal Fluency [11, 14]), executive functions
(Frontal Assessment Battery [15], Stroop Test [16]),
visuospatial abilities (Rey–Osterrieth Complex Fig-
ure Test [17]), praxia (qualitative evaluation), mood
and behavior (Neuropsychiatric Inventory [18]), and
functional performance (Activities of Daily Living
Scale [19]). Conventional 1.5 T MRI was performed:
the degree of medial temporal lobe atrophy was
scored using the Scheltens’ visual rating scale [20],
the global cortical atrophy was assessed by the
Pasquier scale [21], and the vascular burden using
the Fazekas scale [22]. The [18F]FDG-PET scan
was acquired 30 min after injection of [18F]FDG
and the amyloid PET 40 min after injection of
[18F]Florbetapir. Both examinations were carried out
following the standard national and international
guidelines. The PET data were analyzed by two expe-
rienced readers in a consensus reading based on visual
assessment.
With regards to the genetic analysis, genomic DNA
was extracted from peripheral blood leukocytes with
standard procedures, by utilizing a QIAcube sys-
tem (Qiagen, Hilden, Germany). Genetic tests for
FTD causative mutations (MAPT,GRN, C9orf72) and
then for FAD causative mutations (PSEN1, PSEN2,
and APP) were performed following standard pro-
tocol [23]. The Apolipoprotein E (ApoE) genotype
was determined using PCR and HRM, analyzing the
combination of the two single nucleotide polymor-
phisms (rs429358 and rs7412) on the ApoE gene [24].
Lumbar puncture and CSF collection were carried
out according to good clinical practice. CSF sam-
ple was analyzed for total-Tau, phospho-Tau, and
A1-42 by commercial enzyme-linked immunosor-
bent assay (innogenetics ELISA). Cut-off for normal
values were: for total-Tau <300 pg/ml, for phospho-
Tau <60 pg/ml, and for A1-42 >600 pg/ml.
RESULTS
At neurological examination, subcortical reflexes
and left hand resting tremor were evident with-
out other extrapyramidal signs. Neuropsychological
assessment showed significant apathy, anosognosia,
reduced verbal initiative and verbal fluency, long
term memory impairment, slight deficit in executive
functions, and functional decline (incontinence and
self-care deficit). The MMSE score was under the
reference norms (21), the Neuropsychiatric Inventory
score was relatively high (28) because of auditory
delusions, severe apathy, motor and verbal stereo-
typed behaviors, dietary changes, and excessive
daytime sleepiness. The clinical profile was sugges-
tive of early onset dementia in the frontotemporal
spectrum.
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Table 1
Neuropsychological evaluations (individual test results, in brackets raw data) at different time points: the first evaluation was made after
1-year symptoms onset, the second after 1.5-year symptoms onset
Test Score at first evaluation Score at 6-month follow-up Cut-off
Mini-Mental State Examination 20.97 (21/30) 10.97 (11/30) <23.8
Frontal Assessment Battery 13.9 (14/18) 8.9 (9/18) ≤14.30
Digit Span Forward 5.96 (6) 3.96 (4) <4.26
Digit Span Backward 4.02 (4) not evaluable <2.65
Rey Auditory Verbal Learning Test
Immediate Recall 18.2 (19/75) 25.2 (26/75) <28.53
Delayed Recall 0 (0/15) 0 (0/15) <4.69
Babcock Story Recall Test
Immediate Recall (3/28) not tested <6
Delayed Recall (2/28) <9
Rey Osterrieth Complex Figure Test
Copy 19.25 (19/36) not tested <28.88
Delayed Recall 0.25 (2/36) <9.47
Trail Making Test
A (55”) (50”) ≥96”
B 73” (110”)/1 Err not evaluable ≥214 “/≥3 Err
Stroop Test
Time Interference Effect 17.5” (18) not evaluable ≥36.92
Errors Interference Effect (0) not evaluable ≥4.24
Phonemic Word Fluency 6.5 (5) 11.5 (10) <17.35
Semantic Word Fluency 20.5 (19) 14.5 (13) <24
Neuropsychiatric Inventory (28/144) (40/144)
Activities of Daily Living Scale (4/6 preserved) (3/6 preserved)
Brain MRI showed diffuse fronto-temporo-parietal
atrophy (Pasquier score was 14 and the most affected
regions were the fronto-temporals) with bilateral
involvement of hippocampus (Scheltens score was
3 on the right side, 2 on the left side), without evi-
dent vascular burden (Fazekas score was 1) (Fig. 1a).
The MRI pattern was not suggestive for any specific
dementia subtype.
Brain [18F]FDG PET scan (Fig. 1b) revealed severe
bilateral hypometabolism in the anterior prefrontal,
anterior cingulate, medial frontal, orbitofrontal cor-
tices, in the hippocampi, amygdala, temporal pole,
and caudate nuclei (mainly on the right side).
Moderate bilateral hypometabolism in the insula
and posterior cingulate cortex was also evident,
whereas the metabolism in the posterolateral parietal
cortex was preserved. This pattern of predomi-
nantly anterior hypometabolism has been interpreted
as suggestive of neurodegenerative disease not in
the AD spectrum but more likely in the FTD
spectrum.
With regards to CSF biomarkers, A1-42 and
phospho-Tau were within the normal range (respec-
tively, 771 pg/ml and 35 pg/ml), whereas total-Tau
was slightly increased (354 pg/ml); according to cur-
rent evidence, these values and their ratios were
not suggestive of AD (total Tau/A1-42 value (0.46)
was not suggestive of AD profile according to Duits
et al. [25], phospho-Tau/A1-42 value (0.045) was
not suggestive of AD profile according to Tapiola
et al. [26]).
Based on these results and on clinical picture, a
diagnosis of behavioral FTD was made.
Genetic analysis for FTD causative mutations
(MAPT, GRN, C9orf72) was negative. Because of
early onset dementia, genetic analysis for FAD
causative mutations was also performed and revealed
the occurrence of anAPPAla713Thr (g.275329G>A)
heterozygous mutation in the presence of 3/3 ApoE
genotype.
Lastly, amyloid imaging with [18F]Florbetapir
PET was performed and no significant amyloid tracer
retention was found (Fig. 1c). Three years after dis-
ease onset, the clinical picture was characterized
by mutism and compulsive behavior, severe impair-
ment of attention and executive functions, apraxic
gait, and dysautonomic dysfunctions (sweating,
hypersalivation).
According to all the data, an uncertain diagno-
sis of “frontal variant AD”, in the presence of FAD
causative mutation and in the absence of amyloid
biomarkers, has been assumed. Alternatively, based
on the non-genetic biomarkers profile and according
to Rascovsky’s criteria [27], a clinical diagnosis of
possible FTD, behavioral variant, was more likely
postulated.
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Fig. 1. Neuroimaging data a) MRI, axial T2-weighted fluid-attenuated inversion recovery images and coronal T1-weighted image: no
vascular lesions, evidence of cortical and hippocampal atrophy; b) [18F]FDG-PET: severe hypometabolism in frontal lobes, hippocampi and
caudate nuclei; c) [18F]Florbetapir PET: no tracer retention in grey matter.
DISCUSSION
The potential AD pathogenicity ofAPPAla713Thr
(g.275329G>A) variant is confirmed by segregation
of the mutation with the disease [8, 9, 28, 29], absence
of the mutation in control subjects [8, 9, 28], and
results of bioinformatics analysis [30].
This variant is reported in mutation databases
as pathogenic (http://www.molgen.ua.ac.be/ADmuta
tions [31], http://www.alzforum.org/mutations [32],
http://www.hgmd.cf.ac.uk/ [33]); it has been des-
cribed associated with autosomal dominant FAD,
with both early and late onset, and cerebrovascular
lesions. Despite these considerations, asymptomatic
subjects of heterozygous carriers have been reported
[8, 9]; since these cases were mainly younger than
65 years [8] or than the average age at onset of
respective affected family members [9], they cannot
be considered spared from the disease. Moreover, an
incomplete penetrance of the mutation may be sup-
posed in order to explain this phenomenon, as other
genetic or environmental factors could be necessary
for the expression/unexpression of AD phenotype
[7].
In the present case, the genetic diagnosis was in
contrast with the lack of evidence of A pathology
assessed by both CSF analysis and amyloid imag-
ing. Some cases of negative amyloid PET have been
reported in FAD in both Arctic APP mutation carri-
ers [34] and APP Glu693del mutation carriers [35];
also in rare sporadic cases of disease, [11C]Pittsburgh
compound B PET ([11C]PiB PET) failed to show the
expected cerebral amyloid burden [36].
PiB binding was found to be associated to cer-
tain forms of A, such as AN3-pyroglutamate
or high-affinity binding sites which might not be
present in each amyloid plaque [34]. The absence
of [18F]Florbetapir uptake in the present case might
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be related to primary structure diversity of A plaque
due to a protein-coding mutation.
To support a possible diagnosis of AD, it is
assumed that the pathology linked to APP mutation
starts in the brain first with A accumulation, in a
conformation unidentifiable by amyloid PET, and it
is later followed by a reduction in CSF A-clearance,
presumably not detectable at the time of collection
because of not yet started or because of unclassical
A-peptides involvement.
Considering previous autoptic findings in APP
Ala713Thr mutation carriers (relative abundance of
A1-40 deposits compared to A1-42 [8]) and the sup-
posed pathogenic mechanism of the APP Ala713Thr
variant (oligomeric toxicity without alteration in A
ratio [37]), it is conceivable that CSF A1-42 value
remains in the normal range and that CSF A1-40 (not
evaluated in this case) decreases. This hypothesis is
based on the evidence that the reduced A-peptides in
CSF match the peptides accumulated in the amyloid
plaques [38].
Instead of AD diagnosis, the co-occurrence of an
altered A sequence with a FTD phenotype could
suggest an association between APP Ala713Thr
mutation and the FTD pathology. A causative role
of APP Ala713Thr in pathology different from AD
has not been previously supposed, whereas muta-
tion located at the same codon (the APP Ala713Val)
was found associated to schizophrenia with cogni-
tive deficit [39], suggesting that mutations involving
codon 713 can be pleiotropic.
In conclusion, we describe the first case of APP
Ala713Thr mutation carrier associated to both low
[18F]Florbetapir PET uptake and normal A1-42 CSF.
It remains to be clarified whether APP Ala713Thr
mutation is linked to AD without in vivo evidence
of A biomarkers or more likely to other pathol-
ogy as FTD, and the debate is unsolvable without
histopathological examination. Based on our find-
ings, we suggest that in the occurrence of an AD
causative mutation, more than one criterion is nec-
essary for the in vivo evidence of AD pathology and
that pathophysiological biomarkers should be stud-
ied even in carriers of a pathogenic mutation, in order
to confirm the genetic diagnosis or, alternatively, to
suppose other diagnosis and the relative pathogenic
mechanism.
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